| Literature DB >> 35200679 |
Qi Zeng1,2, Yuchan Chen3, Junfeng Wang1, Xuefeng Shi1, Yihao Che1,2, Xiayu Chen1,2, Weimao Zhong1, Weimin Zhang3, Xiaoyi Wei4, Fazuo Wang1, Si Zhang1.
Abstract
Three new metabolites, including a cyclic tetrapeptide asperhiratide (1), an ecdysteroid derivative asperhiratine (2), and a sesquiterpene lactone asperhiratone (3), were isolated and identified from the soft coral-derived fungus Aspergillus hiratsukae SCSIO 5Bn1003, together with 10 known compounds. Their structures were elucidated via spectroscopic analysis, X-ray diffraction analysis, and electronic circular dichroism calculations. In addition, the absolute configuration of 1 was determined by Marfey's technique and an analysis of the acid hydrolysates using a chiral phase HPLC column. Among all the compounds, 6 and 8 showed medium cytotoxic activities against four tumor cell lines (SF-268, HepG-2, MCF-7, and A549), with IC50 values ranging from 31.03 ± 3.04 to 50.25 ± 0.54 µM. Meanwhile, they strongly inhibited α-glucosidase activities, with IC50 values of 35.73 ± 3.94 and 22.00 ± 2.45 µM, which were close to and even stronger than the positive control acarbose (IC50 = 32.92 ± 1.03 µM). Compounds 6-8 showed significant antibacterial activities against Bacillus subtilis, with MIC values of 10.26 ± 0.76 µM, 17.00 ± 1.25 µM, and 5.30 ± 0.29 µM, respectively. Compounds 9 and 12 exhibited potent radical scavenging activities against DPPH, with IC50 values of 12.23 ± 0.78 µM and 7.38 ± 1.16 µM. In addition, asperhiratide (1) was evaluated for anti-angiogenic activities in the in vivo zebrafish model, which showed a weak inhibitory effect on intersegmental vessel (ISV) formation.Entities:
Keywords: Aspergillus hiratsukae; bioactivity evaluation; coral-derived fungi; structure elucidation
Mesh:
Substances:
Year: 2022 PMID: 35200679 PMCID: PMC8877224 DOI: 10.3390/md20020150
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–13.
The 1H and 13C NMR data for 1–3 (700 MHz for 1H and 175 MHz for 13C NMR in CDCl3).
| No. | 1 | 2 | 3 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
| ||
| 1 | 170.1 | - | 37.3 | 1.80 m | 47.9 | - |
| 2 | 124.4 | - | 68.7 | 3.84 m | 37.1 | 2.56 m |
| 3 | 126.6 | 7.51 dd (7.6, 1.4) | 68.5 | 3.96 s | 23.2 | 1.85 m |
| 4 | 122.4 | 7.12 td (7.5,1.1) | 34.2 | 2.10 m | 23.6 | 1.89 m |
| 5 | 131.2 | 7.47 m | 51.8 | 2.40 m | 150.0 | - |
| 6 | 119.9 | 8.28 d (8.2) | 206.3 | - | 47.8 | 2.54 d (5.5) |
| 7 | 136.9 | - | 122.3 | 5.83 d (2.4) | 27.1 | 1.51 d (5.5) |
| 8 | 167.8 | - | 167.5 | 107.4 | 4.58 s | |
| 9 | 68.3 | 4.01 dd (11.1, 3.6) | 35.1 | 1.83 dd (7.4, 3.2) | 12.8 | 0.73 s |
| 10 | 32.6 | 2.86 dd (13.2, 11.3) | 39.3 | - | 84.9 | 4.84 dd (11.6, 3.2) |
| 11 | 138.8 | 21.5 | 1.80 m | 24.1 | 1.68 d (3.0), | |
| 12 | 129.1 | 6.57 d (7.0) | 31.7 | 1.68 m | 28.9 | 1.57 d (3.0) |
| 13 | 128.2 | 7.07 dd (11.2, 4.3) | 50.9 | 36.5 | 2.43 m | |
| 14 | 125.9 | 7.10 dt (2.5, 2.0) | 85.3 | 175.1 | - | |
| 15 | 128.2 | 7.07 dd (11.2, 4.3) | 32.6 | 1.67 m | 17.6 | 1.32 d (7.1) |
| 16 | 129.1 | 6.57 d (7.0) | 21.6 | 2.14 m | ||
| 17 | 39.0 | 2.56 s | 50.9 | 2.43 d (9.2) | ||
| 18 | 168.2 | 18.0 | 0.89 s | |||
| 19 | 49.2 | 5.01 td (10.1, 5.3) | 24.4 | 0.97 s | ||
| 20 | 36.7 | 2.92 dd (13.1,10.5) | 77.7 | |||
| 21 | 127.2 | 21.7 | 1.42 s | |||
| 22 | 130.4 | 7.01, d (8.4) | 79.4 | 5.27 dd (10.9, 2.1) | ||
| 23 | 115.3 | 6.73 d (8.4) | 34.1 | 2.11 m | ||
| 24 | 156.2 | - | 43.2 | 2.20 m | ||
| 25 | 115.3 | 6.73 d (8.4) | 73.5 | 4.25 dd (9.0, 7.7) | ||
| 26 | 130.4 | 7.01 d (8.4) | 181.8 | - | ||
| 27 | 170.2 | - | 41.6 | 2.38 dd (7.1, 2.7) | ||
| 28 | 45.5 | 3.65 dd (5.5, 3.2) | 14.5 | 1.27 d (7.1) | ||
| 1′ | 168.0 | |||||
| 2′ | 131.7 | |||||
| 3′ | 130.8 | 8.10 dd (8.3,1.2) | ||||
| 4′ | 129.7 | 7.51 dd (11.0, 4.6) | ||||
| 5′ | 134.4 | 7.63 m | ||||
| 6′ | 129.7 | 7.51 dd (11.0, 4.6) | ||||
| 7′ | 130.8 | 8.10 dd (8.3,1.2) | ||||
Figure 2Key 1H-1H COSY, HMBC, and NOESY correlations of compounds 1–3.
Figure 3X-ray crystallographic structures of compounds 1–2.
Figure 4Comparison of the experimental ECD spectrum of 3 with the calculated spectra of (1R,2S,6S,10R,13S)- and (1R,2S,6S,10S,13R)-3. R represents computed rotatory strengths.
Cytotoxic activity of compounds against tumor cells a.
| Compounds | IC50 (μM) | |||
|---|---|---|---|---|
| SF-268 | MCF-7 | HepG-2 | A549 | |
|
| 34.75 ± 0.95 | 39.40 ± 0.52 | 43.65 ± 2.08 | 50.25 ± 0.54 |
|
| 31.41 ± 1.98 | 38.57 ± 2.48 | 31.03 ± 3.04 | 32.31 ± 2.36 |
| Adriamycin | 1.19 ± 0.03 | 2.02 ± 0.04 | 1.99 ± 0.07 | 1.73 ± 0.04 |
a The results are mean ±SD (SD = standard deviation). Positive control: adriamycin.
Antioxidative and α-glucosidase inhibitory activities of compounds.
| Compounds | Antioxidative Activity EC50 (µM) | |
|---|---|---|
|
| - | 35.73 ± 3.94 |
|
| - | 22.00 ± 2.45 |
|
| 12.23 ± 0.78 | - |
|
| 7.38 ± 1.16 | - |
| Ascorbic acid a | 11.35 ± 0.56 | - |
| Acarbose b | - | 32.92 ± 1.03 |
a Positive control for antioxidative activity; b positive control for α-glucosidase inhibitory activity.
The antibacterial activities of compounds a.
| Bacterial Species | MIC (µg·mL−1) | |||
|---|---|---|---|---|
| 6 | 7 | 8 | Ciprofloxacin | |
|
| - | 102.86 ± 4.50 | 59.54 ± 0.50 | 0.07 ± 0.001 |
|
| 10.26 ± 0.76 | 17.00 ± 1.25 | 5.30 ± 0.29 | 0.09 ± 0.003 |
a The results are mean ± SD (SD = standard deviation). Positive control: ciprofloxacin.
Figure 5Inhibitory effect of compound 1 on embryonic vascular development of FLI-eGFP transgenic zebrafish. Picture (A,B) (partial enlargement) are positive controls; picture (C,D) (partial enlargement) are treated by compound 1. The red arrows show the damage to vascular development.